Medication Assisted Treatment (MAT). “Medication Assisted Treatment (MAT)” means the use of medications, in combination with counseling and behavioral therapies, to provide a whole-patient approach to the treatment of SUDs.
Medication Assisted Treatment (MAT). The Provider shall provide clinical care for substance use disorders to affected patients. This includes but is not limited to monitoring for and treatment of alcohol, opioid, and benzodiazepine withdrawal using nationally accepted guidelines and tools; medication assisted withdrawal (MAW) and MAT for opioid use disorder; coordination with community-based treatment facilities and opioid treatment programs to ensure seamless transition of patients from community treatment to treatment within DDOC facilities and vice versa. (This includes coordination with opioid treatment programs to ensure methadone continuation for those who received methadone in the community but are now incarcerated). The Provider must ensure that each facility has available (onsite or by telemedicine) a medical provider who is able to evaluate patients with a history suggestive of substance use disorder and to make recommendations to initiate or continue (as appropriate), MAT or MAW within 48 hours of the patients’ incarceration for non-pregnant patients and within 12 hours of incarceration for pregnant patients. It is the Provider’s responsibility to ensure that it has a sufficient number of duly trained providers to meet the needs of all patients with substance use and co-occurring disorders. Refer to BHSAMH Policy F-04 Medically Assisted Withdrawal and Treatment. If the Provider does not have a local Opioid Treatment Program (OTP), it will be required to have a formal arrangement, approved by BHSAMH, with local OTP providers to ensure continuation of treatment for individuals coming into DDOC who were treated with MAT in the community. DDOC requires that the Provider can provide all FDA approved medications for the treatment of substance use disorder including, as appropriate, continuation of those who were on MAT in the community, and induction of therapy for those not previously on MAT, but who would benefit from MAT during incarceration. The Provider will enter a subcontract with a local opioid treatment program or programs that can provide methadone dosing to all DDOC facilities statewide on an on-call basis, including the weekend and holidays. The Provider will ensure the DDOC MAT program is seamless on day one of the contract and beyond. This will require very close collaboration with the BHSAMH, Bureau of Prisons (BOP), Bureau of Community Corrections (BCC), each facility, the pharmaceutical contract provider, and the behavioral healthcare contract provider.
Medication Assisted Treatment (MAT). Is an evidence-based practice that combines pharmacological interventions with substance abuse counseling and social support.
Medication Assisted Treatment (MAT) is a standard of care that is broadly recognized as an essential pillar in any comprehensive approach to the national opioid addiction and overdose epidemic. The State of Michigan seeks to ensure that no consumer is denied access to or pressured to reject the full-service array of evidence-based and potentially life-saving treatment options, including MAT, that are determined to be medically necessary for the individualized needs of that consumer. Treatment options should be discussed in an objective way so each consumer can make an informed decision based on research and outcome data. The State of Michigan expects that PIHP-contracted SUD treatment providers will do the following:
Medication Assisted Treatment (MAT). MAT covers approved medications in combination with behavioral therapies to provide a whole client approach to treating substance use disorders. Clients seeking Outpatient, Residential or Recovery Residences services and have concurrent MAT shall not be delayed access to substance use disorder treatment and recovery services due to the client’s medical status as it relates to MAT. Providers shall develop a policy, which includes how the program informs clients and educates staff about the MAT available at the program if applicable. The policy shall also include the assessment of a client’s MAT needs, administration and storage of medications, and training of staff. Provider staff shall be trained in the area of MAT protocols to include all portions of these standards pertaining to monitoring of persons undergoing detoxification. If, while in treatment, a client exhibits signs and symptoms of withdrawal or behaviors that is a cause for concern for the provider and is believed to be attributable to the client’s medication, the SUS treatment provider staff should address this clinically with the client and the client prescriber. Treatment plans shall be flexible and adjusted as needed with review and consultation by the prescribing physician. Provider staff will regularly communicate with physicians of beneficiaries who are prescribed these medications unless the beneficiary refuses to consent to sign a 42 CFR part 2 compliant release of information for this purpose.
